Our Approach

Ardelyx develops:

Drugs that target proteins found in the gut whose activities affect the entire body
Drugs that are not absorbed, enabling them to achieve systemic efficacy while avoiding systemic toxicity and side effects

Targeted Therapeutic Areas

Ardelyx has established a unique approach to drug development with programs targeting gut transporters, receptors, and enzymes

Therapeutic Areas

Ardelyx News

10/08/2012
AstraZeneca and Ardelyx Announce Worldwide Licensing Deal For NHE3 Inhibitor Programme For Complications Of Renal Disease, Including Diabetes-Induced Renal Disease.

05/24/2012
Ardelyx will present at the European Renal Assocation – European Dialysys and Transplant Association (ERA-EDTA) annual meeting in Paris (France) May 24-27, 2012

04/26/2012
Ardelyx will present at the 22nd European Meeting on Hypertension and Cardiovascular Protection in London (UK) April 26-29, 2012

» See all news

Reduce systemic uptake, minimize side effects.

Ardelyx develops novel, first-in-class oral therapeutics to correct mineral metabolism and metabolic disorders. Our molecules, whose systemic exposure is severely restricted, exploit natural mechanisms of nutrient transport and solute sensing occurring through intestinal epithelia.

Program	Indication	Preclin	Phase 1	Phase 2	Phase 3
RDX5791	• Chronic Kidney Disease	*	*	*	*
	• End Stage Renal Disease	*	*	*	*
	• Heart Failure	*	*	*	*
	IBS-C, Constipation	*	*	*	*
RDX002	Chronic Kidney Disease	*	*	*	*
RDX009	Type 2 Diabetes	*	*	*	*
RDX013	Hyperkalemia CKD	*	*	*	*